Analysts think VERV stock price could increase by 23%
Jul 14, 2025, 11:25 AM
0.95%
What does VERV do
Verve Therapeutics, based in Boston, focuses on gene editing for cardiovascular diseases, employing 255 staff and going public on June 17, 2021. Its lead programs, VERVE-101, VERVE-102, and VERVE-201, target LDL-C-related genes.
9 analysts think VERV stock price will increase by 22.59%. The current median analyst target is $13.52 compared to a current stock price of $11.03. The lowest analysts target is $11.11 and the highest analyst target is $21.00.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.